6:30 PM
 | 
Sep 27, 2012
 |  BC Extra  |  Top Story

FDA approves Bayer's regorafenib

FDA approved Stivarga regorafenib from Bayer AG (Xetra:BAYN) to treat previously treated metastatic colorectal cancer (mCRC) a month ahead of the product's Oct. 27 PDUFA date. Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) has co-promotion rights in the...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >